Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human LRP5 Antibodies:
anti-Mouse (Murine) LRP5 Antibodies:
anti-Rat (Rattus) LRP5 Antibodies:
Go to our pre-filtered search.
Human Monoclonal LRP5 Primary Antibody for FACS, ELISA - ABIN969535
Urano, Shiraki, Usui, Sasaki, Ouchi, Inoue: A1330V variant of the low-density lipoprotein receptor-related protein 5 (LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. in Endocrine journal 2009
Show all 2 Pubmed References
Human Polyclonal LRP5 Primary Antibody for WB - ABIN127323
Del Valle-Pérez, Arqués, Vinyoles, de Herreros, Duñach: Coordinated action of CK1 isoforms in canonical Wnt signaling. in Molecular and cellular biology 2011
Show all 2 Pubmed References
Human Monoclonal LRP5 Primary Antibody for ELISA, WB - ABIN517568
Kim, Goel, Alexander: Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. in PLoS ONE 2011
Human Monoclonal LRP5 Primary Antibody for ELISA, WB - ABIN561692
Badders, Goel, Clark, Klos, Kim, Bafico, Lindvall, Williams, Alexander: The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. in PLoS ONE 2009
The extracellular domains of Lrp5/6 behave as physiologically relevant inhibitors of noncanonical Wnt (show WNT2 Antibodies) signaling during Xenopus and mouse development in vivo.
Rescue experiments showed that LRP5 mutation is associated with hearing loss. (show WNT2 Antibodies)Knocking down lrp5 in zebrafish results in reduced expression of several genes linked to Wnt signaling pathway and decreased cell proliferation when compared with those in wild-type zebrafish
Data show that in zebrafish, lrp5 also controls cell migration during early morphogenetic processes and contributes to shaping the craniofacial skeleton.
This is the first study to report a group of patients with digenic familial exudative vitreoretinopathy (FEVR (show NDP Antibodies)). In most affected eyes, the stage was more severe than stage 3. We speculate that the phenotype of FEVR (show NDP Antibodies) is more severe in patients with digenic rather than monogenic variants of FEVR (show NDP Antibodies)-related genes.
These findings expand the mutation spectrums of ABCA4 (show ABCA4 Antibodies) and LRP5, and will be valuable for genetic counseling and development of therapeutic interventions for patients with Familial exudative vitreoretinopathy.
Data suggest that the risk of type 2 diabetes mellitus (T2DM) may be associated with interactions between the low-density lipoprotein receptor-related protein 5 (LRP5) gene and overweight and obesity.
The data do not support the hypothesis that HBM-causing LRP5 mutations, associated with increased Wnt (show WNT2 Antibodies) signaling, improve glucose metabolism in humans. However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
In conclusion, the LRP5 mutation influences cell proliferation through the Wnt (show WNT2 Antibodies) signaling pathway, thereby reducing the number of supporting cells and hair cells and leading to nonsyndromic hearing loss in this Chinese family.
LRP5 might be an important genetic marker contributing to bone mass accrual early in life.
We identified two novel heterozygous deletion mutations [LRP5, c.4053 DelC (p.Ile1351IlefsX88); TSPAN12 (show TSPAN12 Antibodies), EX8Del] using targeted NGS as a causative mutation for Familial exudative vitreoretinopathy (FEVR (show NDP Antibodies)).
A novel heterozygous mutation (p.N198Y) in LRP5 was identified in a patient with significantly increased bone mineral density.
The presence of GIIA in the LRP5 complex pinpoints a potential functional connection with PRKCSH (show PRKCSH Antibodies). Interestingly, all three PLD (show PLD Antibodies)-associated protein complexes included filamin A (FLNA (show FLNA Antibodies)), a multifunctional protein described to play a role in ciliogenesis as well as canonical Wnt (show WNT2 Antibodies) signalling.
LRP5 (rs556442) had a significant influence on trigylceride (TG) levels in unadjusted analysis and when adjusted for interacting factors. Higher TG levels were observed in AA/AG genotype of rs566442 in comparison to GG genotype (OR = 2.028, 95% CI = 0.997-4.127, p = 0.049).
Heterozygous deletion of the LRP5 gene in mice could alter the profile of the immune cells, influence the balance of immune environment, and modulate bone homeostasis.
Megakaryocytes are increased in the bone marrow of Lrp5G170V/G170V mice. Depletion of megakaryocytes does not affect the Lrp5-induced high bone mass.
The phenotype of the Lrp5(tvrm111B) mutant includes abnormalities of the retinal vasculature and of bone mineral density.
the LRP5 mutation in high bone mass transgenic mice shows altered bone matrix composition
Lrp6 (show LRP6 Antibodies) is the key mediator of Wnt3a (show WNT3A Antibodies) signaling in osteoblasts and Lrp5 played a less significant role in mediating Wnt3a (show WNT3A Antibodies) signaling.
Identification of a link between Wnt (show WNT2 Antibodies)-Lrp5 signaling and insulin (show INS Antibodies) signaling in the osteoblast that has the potential to influence energy balance and compound the detrimental effects of a HFD on whole-body metabolism.
Lrp5(-/-) mice displayed significantly delayed retinal vascular development, absence of deep layer retinal vessels, leading to increased levels of vascular endothelial growth factor (show VEGF Antibodies) and subsequent pathologic glomeruloid vessels, as well as decreased inner retinal visual function.
A mouse LRP5 ectodomain recombinant was cleaved by VAP1 (show AOC3 Antibodies), creating a peptide, VAHLTGIHAVEE, detected by mass spectrometric analysis of the 140-kDa fragment, suggesting that the sessile bond by VAP1 (show AOC3 Antibodies) is Glu1206-Val1207.
we revealed miR (show MLXIP Antibodies)-375-3p negatively regulated osteogenesis by targeting LRP5 and beta-catenin (show CTNNB1 Antibodies)
lung myeloid cells are responsive to Lrp5/beta-catenin (show CTNNB1 Antibodies) signaling, leading to differentiation of an alveolar macrophage subtype that antagonizes the resolution of lung fibrosis.
This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy.
Lipoprotein Receptor Related Protein 5
, low density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5-like
, low density lipoprotein receptor-related protein 7
, low-density lipoprotein receptor-related protein 7